Brief: Sinomab Bioscience Says Investigational New Drug Application For Sm17 Was Accepted
16/02/2022 15:18
Feb 16 (Reuters) - SinoMab BioScience Ltd 3681.HK :
* ON 11 FEB, INVESTIGATIONAL NEW DRUG APPLICATION FOR SM17
WAS
ACCEPTED BY CENTER FOR DRUG EVALUATION AND RESEARCH, U.S. FDA
* CO PLANS TO INITIATE FIRST-IN-HUMAN STUDY FOR SM17 IN U.S.
IN Q1
OF 2022
Source text for Eikon: ID:nHKS7fFVJj
Further company coverage: 3681.HK
((reuters.briefs@thomsonreuters.com;))
Recent news on Sinomab Bioscience
See all newsBrief: Sinomab Bioscience Posts HY Loss Of RMB127.4 Million
Brief: Sinomab Bioscience Says Fang Liang Resigns As Executive Director
Brief: Sinomab Bioscience Announces Major Deal For Disposal Of Suzhou Property And Facility For RMB280 MLN
Brief: SinoMab Bioscience Appoints Fang Liang As Executive Director
Brief: Hainan Haiyao Plans To Unload Stake In Sinomab Bioscience